SIRT6 Suppresses NFATc4 Expression and Activation in Cardiomyocyte Hypertrophy

Abstract

NFATc4, a member from the Nuclear Factor of Activated T cells (NFATs) transcription factor family, plays a pivotal role in the development of cardiac hypertrophy. NFATc4 is dephosphorylated by calcineurin and translocated from the cytoplasm to the nucleus to regulate the expression of hypertrophic genes, like brain natriuretic polypeptide (BNP). The present study identified SIRT6, an important subtype of NAD+ dependent class III histone deacetylase, to be a negative regulator of NFATc4 in cardiomyocyte hypertrophy. In phenylephrine (PE)-induced hypertrophic cardiomyocyte model, overexpression of SIRT6 by adenovirus infection or by plasmid transfection repressed the protein and mRNA expressions of NFATc4, elevated its phosphorylation level, prevented its nuclear accumulation, subsequently suppressed its transcriptional activity and downregulated its target gene BNP. By contrast, mutant of SIRT6 without deacetylase activity (H133Y) did not demonstrate these effects, suggesting that the inhibitory effect of SIRT6 on NFATc4 was dependent on its deacetylase activity. Moreover, the effect of SIRT6 overexpression on repressing BNP expression was reversed by NFATc4 replenishment, whereas the effect of SIRT6 deficiency on upregulating BNP was recovered by NFATc4 silencing. Mechanistically, interactions between SIRT6 and NFATc4 might possibly facilitate the deacetylation of NFATc4 by SIRT6, thereby preventing the activation of NFATc4. In conclusion, the present study reveals that SIRT6 suppresses the expression and activation of NFATc4. These findings provide more evidences of the anti-hypertrophic effect of SIRT6 and suggest SIRT6 as a potential therapeutic target for cardiac hypertrophy.

The poly(ADP-ribosyl)ation of BRD4 mediated by PARP1 promoted pathological cardiac hypertrophy

“…Western blot assays were performed as previously reported 30 . For Western blotting, primary antibodies against BRD4 (Cat#128874; rabbit, diluted 1:1000), PARP1 (Cat#9532S; rabbit, diluted 1:1000), RNA Pol Ⅱ (Cat#2629; mouse, diluted 1:1000) was purchased from Cell signaling Technology.…”

Bawei Chenxiang Wan Ameliorates Cardiac Hypertrophy by Activating AMPK/PPAR-α Signaling Pathway Improving Energy Metabolism

“…Western blotting assay was performed as previously described ( Feng et al, 2015 ; Li et al, 2018 ). Equal amount of proteins (30 mg of total proteins) was separated by 8% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE), and then transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore).…”

Emerging roles of SIRT6 in human diseases and its modulators

“…The downregulation of p300 protein subsequently inhibited the transcriptional activity of NF‐κB p65 subunit, hence protecting cardiomyocytes from hypertrophy by angiotensin II (Ang II) or phenylephrine stimulation 205,207 . In addition to inhibiting AKT signaling, SIRT6 acts as a negative regulator in cardiomyocyte hypertrophy by suppression of NFATc4 expression and transcriptional activity, as well as preventing the activation of STAT3 signaling 208,209 . SIRT6‐induced autophagy also plays a protective role in isoproterenol‐induced cardiac hypertrophy.…”